Tirzepatide weight loss: what 75kg to 58kg actually requires

What's this video probably claiming?

Based on the caption showing a weight drop from 75kg to 58kg, this creator is almost certainly documenting a personal tirzepatide weight loss journey. The "one last try" framing suggests prior failed weight loss attempts, which is an extremely common narrative structure in the #tirzepatidejourney space. We're likely looking at before/after progress content, possibly including dose progression, timeline details, side effect experiences, and lifestyle changes alongside the medication. The 17kg loss (roughly 37 pounds) is a significant but not implausible result, depending on starting body composition, duration of use, and whether the creator combined the medication with dietary changes. What's harder to verify from the caption alone is the timeframe, the doses used, whether this was brand-name Zepbound or compounded tirzepatide, and what other factors contributed. Those details matter enormously when viewers are inevitably asking themselves whether they'd get similar results.

What does the science actually show?

Tirzepatide's weight loss data is genuinely impressive by clinical trial standards. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) followed 2,539 adults with obesity over 72 weeks. At the highest dose of 15mg weekly, participants lost an average of 20.9% of body weight. At 10mg, it was 19.5%, and at 5mg, 15%. These are average figures, which means a meaningful portion of participants lost more, and a meaningful portion lost less. Starting weight matters too: a 17kg loss from 75kg represents roughly 22.7% body weight reduction, which falls near the top end of average outcomes at higher doses. Real-world results, documented in analyses like Blonde et al. (2023, Diabetes Care), tend to be somewhat lower than trial results because adherence is messier outside controlled settings. The mechanism involves dual GIP and GLP-1 receptor agonism, which appears to suppress appetite more effectively than GLP-1 alone.

Where does the social media noise diverge from clinical reality?

The biggest distortion in tirzepatide content is survivorship bias. Creators who lost 17kg are posting. People who quit at week 6 due to nausea, who plateaued at 5kg, or who regained weight after stopping are largely not making viral TikToks. This creates a skewed reference point for viewers estimating their own likely outcomes. There's also consistent underreporting of the rebound data. A SURMOUNT-4 withdrawal study (Aronne et al., 2024, JAMA) found participants who stopped tirzepatide regained approximately two-thirds of their lost weight within a year. That context is almost never part of a before/after success video. Additionally, many creators don't distinguish between brand-name tirzepatide and compounded versions, which are not FDA-approved equivalents and have faced significant regulatory scrutiny from the FDA in 2024 and 2025 regarding their legal status and quality standards.

What should you actually know?

A 17kg loss on tirzepatide is within the range of what clinical evidence supports, so the headline number here isn't the problem. The problems are context and completeness. First, tirzepatide requires a valid prescription from a licensed provider following proper clinical evaluation. Second, common side effects including nausea, vomiting, and diarrhea affect a substantial portion of users, with SURMOUNT-1 showing gastrointestinal adverse events in roughly 80% of participants at higher doses, though most were mild to moderate. Third, the medication appears to work primarily by reducing appetite, not by changing metabolism permanently, which is why ongoing use is typically required to maintain results. Fourth, individual response varies considerably based on genetics, starting weight, adherence, and dietary habits. A creator's specific result is not a prediction for your result. If you're considering tirzepatide, the conversation should be with a licensed clinician reviewing your full health picture, not a comment section.